Open an account

Arcutis Biotherapeutics

ARQT · NASDAQ

$32.82+$0.93 (+2.92%)TodayMarket closed ·
Prev close $31.89

About ARQT

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 354 full-time employees. The company went IPO on 2020-01-31. The firm is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.

Employees
354
Headquarters
Westlake Village, California
Listed
Jan 31, 2020
Sector
Health Care
Industry
Biotechnology
Website
arcutis.com

ARQT key statistics

Market cap
4.13B
Price-earnings ratio
151.86
Dividend yield
—
Average volume
2.39M
Volume
4.49M
Open price
$31.89
High today
$33.30
Low today
$31.75
52 Week high
$33.01
52 Week low
$19.30

Arcutis Biotherapeutics (ARQT) at a glance

As of Oct 20, 2026, Arcutis Biotherapeutics (ARQT) shares are priced at $32.82, giving the company a market cap of 4.13B and a price-to-earnings ratio of 151.86.

Today the stock has traded between $31.75 and $33.30. The current price is 3.4% above the day's low and 1.4% below its high.

Volume so far is 4.49M shares, above the average of 2.39M shares a day.

Over the past year Arcutis Biotherapeutics has ranged from $19.30 to $33.01, and now sits 99% of the way up that range.

Arcutis Biotherapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.11 per share against an estimate of $0.0439.

The average analyst price target is $37.74, 15.0% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

88%of 8 analyst ratings say Buy
  • Buy87.5%
  • Hold12.5%
  • Sell0.0%
Price target · 9 analystsAvg $37.74
Low
$34.34
Now
$32.82
High
$42.00

ARQT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 62.2% on average.

  1. Q3 FY24: reported -$0.33 per share against an estimate of -$0.4255
  2. Q4 FY24: reported -$0.09 per share against an estimate of -$0.2601
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.2142
  4. Q2 FY25: reported -$0.13 per share against an estimate of -$0.1613
  5. Q3 FY25: reported $0.06 per share against an estimate of -$0.1019
  6. Q4 FY25: reported $0.13 per share against an estimate of $0.1157
  7. Q1 FY26: reported -$0.09 per share against an estimate of -$0.0838
  8. Q2 FY26: reported $0.11 per share against an estimate of $0.0439

ARQT news

  • Vandana Singh

    Why Is Arcutis Biotherapeutics Stock Surging Thursday?

  • Press releasePRNewswire

    Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Press releaseGlobe Newswire

    The Credibility Filter Wall Street Uses to Sort Biotech Winners

  • 12 Health Care Stocks Moving In Wednesday's After-Market Session

  • Preview: Arcutis Biotherapeutics's Earnings

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Avi Kapoor

    Crude Oil Falls Over 2%; PayPal Shares Spike Higher

Similar companies

Companies in the same industry as Arcutis Biotherapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.